Zentalis Pharmaceuticals Inc · Q4 2021 earnings

Briefing

Zentalis reported financial results for Q4 and full year 2021, highlighting the Fast Track designation granted to ZN-c3 and the addition of a preclinical BCL-xL degrader candidate.

Zentalis Pharmaceuticals reported its Q4 and full year 2021 financial results, with a cash, cash equivalents, and marketable securities position of $339.9 million as of December 31, 2021. Research and development expenses for the year ended December 31, 2021 were $175.6 million, and general and administrative expenses were $40.9 million.

• Fast Track designation was granted by the FDA to ZN-c3 for the treatment of uterine serous carcinoma.
• Two additional trials with ZN-c3 were initiated, including a Phase 2 trial and a Phase 1/2 trial in combination with niraparib in ovarian cancer.
• A preclinical BCL-xL heterobifunctional degrader candidate was added to the pipeline.
• The company ended the year with $339.9 million in cash, cash equivalents, and short-term investments.

Headline financials

Revenue & EPS history

Zentalis believes that its existing cash, cash equivalents and marketable securities as of December 31, 2021 will be sufficient to fund our operating expenses and capital expenditures requirements into the third quarter of 2023.